John melo

Biotech firm Amyris Inc. (NASDAQ: AMRS) is clapping back at allegations made by Lavvan Inc. that it committed patent infringment. "Amyris is disappointed that LAVVAN has chosen the public domain to articulate its position," Amyris CEO John Melo said in a statement Friday. "...